In contrast, the combination of EGFR mAbs and ICIs in various cancer types (including CRC, HNSCC, and NSCLC) demonstrated promising clinical efficacy (improved median PFS) without significant adverse effects (Table 1) [93,94,95,96]. Here, EGFR is linked to cancer.